Photo: Courtesy of Teva

27 July 2015Asia

Teva buys Allergan Generics in $40bn deal

Pharmaceutical company Teva has bought Allergan Genericsfrom drugs business Allerganin a $40.5 billion deal.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Allergan sees off glaucoma patent challenges

5 August 2015 Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan.

Teva fails to reclassify MS drug to thwart generics

5 January 2021 Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

More on this story

Allergan sees off glaucoma patent challenges

5 August 2015 Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan.

Teva fails to reclassify MS drug to thwart generics

5 January 2021 Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

More on this story

Allergan sees off glaucoma patent challenges

5 August 2015 Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan.

Teva fails to reclassify MS drug to thwart generics

5 January 2021 Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent